Early Intratracheal Budesonide to Reduce Bronchopulmonary Dysplasia in Extremely Preterm Infants

Overview of attention for article published in JAMA: Journal of the American Medical Association, October 2025

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (98th percentile)
Good Attention Score compared to outputs of the same age and source (74th percentile)

Mentioned by

news: 3 news outlets
blogs: 3 blogs
twitter: 43 X users

facebook: 2 Facebook pages
guideline: 1 clinical guideline source
bluesky: 10 Bluesky users

Readers on

mendeley: 13 Mendeley

So far, Altmetric has seen 51 X posts from 43 X users, with an upper bound of 686,201 followers.

In extremely preterm infants, adding budesonide to surfactant does not reduce BPD or death. This large trial, stopped for futility, found no benefit, only an increased risk of hyperglycemia. A practice-changing finding. https://t.co/iF2qdp19wD

Budesonide Plus Surfactant Fails to Reduce BPD or Death in Extremely Preterm Infants, Raises Hyperglycemia Risk by Ambalavanan N, Carlo WA (...) Walsh MC et 35 al. in JAMA https://t.co/waaWszRmcf #MedX #MedResearch

https://t.co/OiTcbdejL9

RT @JAMA_current: In extremely preterm infants, intratracheal budesonide mixed with surfactant did not reduce bronchopulmonary dysplasia or…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 47 additional X posts.